Support & Savings for Patients

We offer a number of financial assistance and savings programs to help eligible patients start and stay on treatment. Whether a patient is awaiting insurance approval prior to the start of treatment or looking for financial support to stay on treatment, we’re here to help.

Help for eligible patients who demonstrate financial need.

Eligible patients can receive free medication. Offer is valid for one year from date of enrollment and renewed on an annual basis for income eligible patients until program expiration or when insurance coverage is obtained.Patient Assistance Program (PAP) Details:

  • Patient must have a valid prescription for Saizen® (somatropin) for injection
  • Patient must be 18 years of age or under
  • Patients will be denied eligibility for the program if they have prescription insurance coverage unless the insurance coverage does not cover Saizen® (somatropin) for injection, in which case the patient will be eligible for the program
  • All determinations about insurance coverage will be made during the CFG reimbursement casework processes
  • Must provide number of people in household for the income eligibility determination. If this value is missing, the application is incomplete.
  • Programs are available only for prescriptions filled in the United States
  • Patients may not combine a program offer with any other rebate, coupon, free trial, or similar offer
  • EMD Serono reserves the right to rescind, revoke, or amend a program at any time without notice
  • Offer not valid for prescriptions that may be reimbursed under a federal or state healthcare program, including Medicare, Medicaid, or any other similar federal or state healthcare program, including any state medical pharmaceutical assistance program
  • Void in any state where prohibited by law, taxed, or otherwise restricted
  • These are not insurance programs

Patients may call 1-800-582-7989 to discover how Connections for Growth® can help them get started.

Eligible patients may save up to $200 off their monthly co-pay or co-insurance for 12 months after program activation, for a total of up to $2,400 for Saizen® (somatropin) for injection.

The easy Savings Co-Pay Program provides assistance to insured patients filling 30-, 60-, or 90-day prescriptions. Significant savings on co-pay or co-insurance: $200 off monthly co-pay or co-insurance for 12 months after program activation, for a total of up to $2,400 for Saizen®.

easy Savings Co-Pay Program Details:

  • Patients must have a valid prescription for Saizen®.
  • Program may save patients up to $200 per month on their co-pay or co-insurance costs. This can mean a savings of up to $2,400 depending on patient’s co-payment.
  • Patients are eligible for a total maximum benefit of $2,400 for the lifetime of the program. If patients have already been enrolled in the program, the benefit they have already received will be deducted from the total maximum benefit.
  • Eligible patients must have a prescription drug benefit that covers Saizen®.
  • Valid for 1 year from patient enrollment or until program expires.
  • Save up to $200 each time a patient fills a 30-day Saizen® prescription. Patients filling a 60-day or 90-day prescription are eligible for up to $400 and up to $600 off, respectively.
  • Patients may not use program if their private insurance, HMO, or other health or pharmacy benefit program paid for the entire Saizen® prescription.
  • Programs are available only for prescriptions filled in the United States.
  • Patients may not combine a program offer with any other rebate, coupon, free trial, or similar offer.
  • EMD Serono reserves the right to rescind, revoke, or amend a program at any time without notice.
  • Offer not valid for prescriptions that may be reimbursed under a federal or state healthcare program, including Medicare, Medicaid, or any other similar federal or state healthcare program, including any state medical pharmaceutical assistance program.
  • Void in any state where prohibited by law, taxed, or otherwise restricted.
  • These are not insurance programs.

Patients may call 1-800-582-7989 to discover how Connections for Growth® can help them get started.

Helping eligible cash-paying patients save on medication costs.

Self-Pay Support Program Details and Rules

  • Program is available only for prescriptions filled in the United States
  • Patients shall be required to pay no more than $23 per milligram of Saizen®
  • EMD Serono reserves the right to rescind, revoke, terminate, or amend the program at any time without notice
  • The program will cover the following products:

    • Saizen® 5 mg vial
    • Saizen® 8.8 mg via
  • No limit on the number of times the program may be used by a patient
  • A program offer may be used once every 21 days
  • The program is available only for self-pay patients with a valid Saizen® prescription; offer not valid for prescriptions that may be reimbursed under a commercial insurance program
  • Offer not valid for prescriptions that may be reimbursed under a federal or state healthcare program, Including Medicare, Medicaid, or any other similar federal or state healthcare program, Including any state medical pharmaceutical assistance program
  • Offer not valid in conjunction with other EMO Serono offers including the Saizen® CoPay Savings Program
  • If you have further questions on how to use the offer, call Trial Card, Inc. at 1-866-562-6188
  • The program information sheet is only valid at a pharmacy that has contracted with TrialCard, Inc. to accept the discount and may only be redeemed by TrialCard, Inc.
  • Void in any state where prohibited by law, taxed, or otherwise restricted

This program is not insurance.

* Offer may be used once every 21 days until program is revoked. expires or terminated by EMD Sereno.

Patients may call 1-800-582-7989 to discover how Connections for Growth® can help them get started.

Connections for Growth® Supports PatientsConnections for Growth Connections for Growth® is staffed by highly trained patient support representatives, insurance reimbursement specialists and device trainers. Together, this team provides callers with educational materials, treatment information, reimbursement support, cool.click® 2 refill supplies, and device trainer referrals.

Patients may call 1-800-582-7989 to access Connections for Growth® support services.

  • Multilingual support
  • On-call nurses to answer device-related questions
  • In a 2010 patient survey, 97% of Saizen® patients were either completely or very satisfied with Connections for Growth® support services 1

  • Individually assigned to be a familiar voice throughout treatment
  • Provides customized prior authorization and reauthorization support
  • In-home injection training

  • Submits insurance paperwork and helps to obtain timely approval
  • Facilitates the reimbursement process between patients, the insurance companies and doctors’ offices
  • Handles denied benefits and helps to start the most effective appeal path

INDICATIONS AND USAGE:

Saizen® (somatropin) for injection is indicated for the treatment of pediatric patients and adults with growth hormone deficiency (GHD). Confirmation of adult growth hormone deficiency involves using provocative testing in patients without organic disease or congenital/genetic etiology. Continuation of treatment in adults treated in childhood should be at a reduced recommended dose.

IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

Saizen should not be used in patients with acute critical illness, Prader-Willi syndrome, active malignancy, hypersensitivity to somatropin or any of its excipients, diabetic retinopathy or papilledema, or with children with closed epiphyses. Saizen is reconstituted with Bacteriostatic Water for Injection and should not be administered to patients with a known sensitivity to benzyl alcohol.

WARNINGS AND PRECAUTIONS

Acute Critical Illness: Increased mortality has been reported in patients with acute critical illness due to complications following surgery, multiple accidental trauma, or acute respiratory failure.

Prader-Willi Syndrome: Fatalities have been reported in patients with Prader-Willi syndrome who were also obese or had history of an upper airway obstruction, sleep apnea, or unidentified respiratory infection.

Neoplasms: Patients with pre-existing tumors should be monitored for progression or reoccurrence, in particular, meningiomas. Monitor patients carefully for preexisting nevi.

Glucose Intolerance/Diabetes Mellitus: Previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during treatment. Glucose levels should be monitored periodically in all patients treated with somatropin, especially in those with risk factors for diabetes mellitus.

Intracranial Hypertension: Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported. Funduscopic examination should be performed prior to initiating treatment with Saizen and periodically during the course of treatment. If papilledema is observed, treatment should be stopped and restarted at a lower dose after IH-associated symptoms have resolved.

Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs.

Fluid Retention: Fluid retention in adults may occur. Clinical manifestations (e.g. edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paraesthesias) are usually transient and dose dependent.

Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of somatropin.

Hypothyroidism: Patients should be monitored closely for the onset or worsening of hypothyroidism.

Slipped Capital Femoral Epiphysis and Progress of Preexisting Scoliosis: Slipped capital femoral epiphysis and progression of scoliosis may occur more frequently in patients undergoing rapid growth.

Reevaluation of Childhood Onset Adult GHD: Patients with epiphyseal closure who were treated with somatropin replacement therapy in childhood should be reevaluated.

Lipoatrophy: Rotate the injection site to avoid tissue atrophy. Inform patients that prompt medical attention should be sought if allergic reactions occur.

Laboratory Tests: Serum levels of inorganic phosphorus, alkaline phosphatase, parathyroid hormone (PTH), and IGF-1 may increase with somatropin therapy.

Pancreatitis: Cases of pancreatitis have been reported rarely. Consider pancreatitis in patients who develop persistent severe abdominal pain.

Benzyl Alcohol: Benzyl alcohol has been associated with serious adverse events including gasping syndrome and death, particularly in pediatric patients and neonates.

ADVERSE REACTIONS

Adverse events reported in pediatric GHD clinical studies included injection site reactions (such as pain, numbness, redness and swelling), hypothyroidism, hypoglycemia, seizures, exacerbation of preexisting psoriasis and fluid retention. Arthralgia, myalgia, headache, peripheral edema, other types of edema, carpal tunnel syndrome, paresthesia, hypoesthesia, and glucose intolerance were reported in >5% of patients of adult patients treated with Saizen.

SPECIAL POPULATIONS

Somatropin should be used during pregnancy only if clearly needed and with caution in nursing mothers because it is not known whether somatropin is excreted in human milk. The safety and effectiveness of somatropin in patients with hepatic or renal impairment or in patients aged 65 years and over have not been evaluated in clinical studies.

Please see the Full Prescribing Information for a complete discussion of Saizen risks. Refer to the Instructions for Use for educating patients how to administer Saizen.

1. Data on File